Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelareorep + Pembrolizumab + Chemotherapy in Advanced Pancreatic Adenocarcinoma
NCT02620423Phase 1Completed
- Sponsor
- Oncolytics Biotech Inc.
- Start
- Dec 2015
- Primary completion
- Mar 2018
- Modality
- Oncolytic Viruses, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pelareorep in pancreatic adenocarcinoma (PDAC), sponsored by Oncolytics Biotech Inc. Primary endpoint: Safety and Dose Limiting Toxicities. Started Dec 2015; status: completed.
02
Drugs
pelareorep
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02620423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02620423.